AMD3100, the first FDA-approved CXCR4 small-molecule inhibitor, is widely used for stem cell mobilization and harvesting, which has evolved from an immunomodulator to a promising anticancer agent.434 Its utility extends beyond monotherapy, showing significant synergies when combined with other anticancer agents, thereby amplifying therapeutic efficacy.435 For example, in pancreatic cancer, Feig et al. identified CXCL12 as a critical factor in immunosuppression, produced mainly by FAP+ CAFs and preventing T-cell infiltration into tumor regions. Here, CXCR4 is linked to neoplasm.